Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team of our neuroimaging researchers will lead this study, which has received a grant from the University of Oxford's COVID-19 Research Response Fund.

MRI scanner from the control room

COVID-19 adversely affects the brain. Around 36 per cent of hospitalised patients show symptoms ranging from loss of sense of smell, to strokes, and seizures. Concerns are growing that COVID-19 may cause long-term harmful neurological effects including cognitive impairment, mental health disorders, and chronic breathing difficulties. This may arise from the direct viral invasion of the brain, or autoimmune responses to the infection, or indirect effects of severe systemic illness.

Using magnetic resonance imaging (MRI), a team led by Associate Professor Kyle Pattinson will quantify brain abnormalities associated with COVID-19 infection. Their aim is to collect proof-of-concept data that will leverage funding for further multi-centre research collaborations. The eventual outcome will be brain markers to direct individualised treatments improving both short- and long-term outcomes from COVID-19.

The team will undertake two observational studies: an acute study in hospitalised patients and a follow-up study, using high-resolution brain-stem MRI, performed 3-6 months later, after patients have been discharged from hospital. In this way, the researchers will be able to characterise the brain structural, functional, and cerebrovascular effects of COVID-19 infection, establish quantitative relationships between clinical/bedside measures of COVID-19 and neuroimaging measures, and provide preliminary data sets for future discovery of novel biomarkers.

Similar stories

Attention and memory deficits persist for months after recovery from mild COVID

Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.

New Academic Visitor from Nigeria

Associate Professor of Radiology, Godwin Ogbole has arrived on a six-month visit to the Nuffield Department of Clinical Neurosciences, as part of the Africa Oxford Initiative.

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Funding received for research into Motor Neuron Disease

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

New Year's Honours for Professor Irene Tracey

Professor Irene Tracey FMedSci, MAE, Professor of Anaesthetic Neuroscience and Warden of Merton College, has been appointed CBE for services to medical research.

Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.